Cytotoxic T Cells Activated by Self-differentiated Monocytederived Dendritic Cells Against Multiple Myeloma Cells

Wannasiri Chiraphapphaiboon; Piriya Luangwattananun; Aussara Panya; Niphat Jirapongwattana; Primana Punnakitikashem; Thaweesak Chieochansin; Mutita Junking; Pa Thai Yenchitsomanus

doi:10.21873/anticanres.15655

Cytotoxic T Cells Activated by Self-differentiated Monocytederived Dendritic Cells Against Multiple Myeloma Cells

Wannasiri Chiraphapphaiboon
, Piriya Luangwattananun
, Aussara Panya
, Niphat Jirapongwattana
, Primana Punnakitikashem
, Thaweesak Chieochansin
, Mutita Junking
, Pa Thai Yenchitsomanus

Siriraj Hospital
Chiang Mai University

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background/Aim: B cell maturation antigen (BCMA) is an ideal target for adoptive T cell therapy of multiple myeloma (MM). In this study, we evaluated self-differentiated monocyte-derived dendritic cells expressing BCMA (SD-DC-BCMA) to activate T cells for killing MM cells. Materials and Methods: Lentivirus-modified SD-DC-BCMA harboring tri-cistronic cDNAs encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and BCMA was generated. Cytotoxicity of T cells activated by SD-DC-BCMA against MM cells was evaluated. Results: T cells activated by SD-DC-BCMA exhibited a dose-dependent cytotoxicity against BCMA-expressing MM cells and produced high IFN-γ levels, compared to inactivated T cells or control T cells. A significantly higher killing ability of T cells activated by SD-DC-BCMA was further demonstrated in BCMA-overexpressing cells when compared with BCMA-negative cells. Conclusion: The potency of SD-DC-BCMA to activate T cells for antigen-specific cancer killing provides a framework for therapeutic application of adoptive T cell therapy in MM.

Original language	English
Pages (from-to)	1785-1799
Number of pages	15
Journal	Anticancer Research
Volume	42
Issue number	4
DOIs	https://doi.org/10.21873/anticanres.15655
Publication status	Published - Apr 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

B cell maturation antigen
Multiple myeloma
adoptive T cell therapy
cytotoxic T cells
dendritic cells

Access to Document

10.21873/anticanres.15655

Cite this

@article{66ddea11422e4eb4afd69c14fcecda91,

title = "Cytotoxic T Cells Activated by Self-differentiated Monocytederived Dendritic Cells Against Multiple Myeloma Cells",

abstract = "Background/Aim: B cell maturation antigen (BCMA) is an ideal target for adoptive T cell therapy of multiple myeloma (MM). In this study, we evaluated self-differentiated monocyte-derived dendritic cells expressing BCMA (SD-DC-BCMA) to activate T cells for killing MM cells. Materials and Methods: Lentivirus-modified SD-DC-BCMA harboring tri-cistronic cDNAs encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and BCMA was generated. Cytotoxicity of T cells activated by SD-DC-BCMA against MM cells was evaluated. Results: T cells activated by SD-DC-BCMA exhibited a dose-dependent cytotoxicity against BCMA-expressing MM cells and produced high IFN-γ levels, compared to inactivated T cells or control T cells. A significantly higher killing ability of T cells activated by SD-DC-BCMA was further demonstrated in BCMA-overexpressing cells when compared with BCMA-negative cells. Conclusion: The potency of SD-DC-BCMA to activate T cells for antigen-specific cancer killing provides a framework for therapeutic application of adoptive T cell therapy in MM.",

keywords = "B cell maturation antigen, Multiple myeloma, adoptive T cell therapy, cytotoxic T cells, dendritic cells",

author = "Wannasiri Chiraphapphaiboon and Piriya Luangwattananun and Aussara Panya and Niphat Jirapongwattana and Primana Punnakitikashem and Thaweesak Chieochansin and Mutita Junking and Yenchitsomanus, \{Pa Thai\}",

year = "2022",

month = apr,

doi = "10.21873/anticanres.15655",

language = "English",

volume = "42",

pages = "1785--1799",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "4",

}

TY - JOUR

T1 - Cytotoxic T Cells Activated by Self-differentiated Monocytederived Dendritic Cells Against Multiple Myeloma Cells

AU - Chiraphapphaiboon, Wannasiri

AU - Luangwattananun, Piriya

AU - Panya, Aussara

AU - Jirapongwattana, Niphat

AU - Punnakitikashem, Primana

AU - Chieochansin, Thaweesak

AU - Junking, Mutita

AU - Yenchitsomanus, Pa Thai

PY - 2022/4

Y1 - 2022/4

N2 - Background/Aim: B cell maturation antigen (BCMA) is an ideal target for adoptive T cell therapy of multiple myeloma (MM). In this study, we evaluated self-differentiated monocyte-derived dendritic cells expressing BCMA (SD-DC-BCMA) to activate T cells for killing MM cells. Materials and Methods: Lentivirus-modified SD-DC-BCMA harboring tri-cistronic cDNAs encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and BCMA was generated. Cytotoxicity of T cells activated by SD-DC-BCMA against MM cells was evaluated. Results: T cells activated by SD-DC-BCMA exhibited a dose-dependent cytotoxicity against BCMA-expressing MM cells and produced high IFN-γ levels, compared to inactivated T cells or control T cells. A significantly higher killing ability of T cells activated by SD-DC-BCMA was further demonstrated in BCMA-overexpressing cells when compared with BCMA-negative cells. Conclusion: The potency of SD-DC-BCMA to activate T cells for antigen-specific cancer killing provides a framework for therapeutic application of adoptive T cell therapy in MM.

AB - Background/Aim: B cell maturation antigen (BCMA) is an ideal target for adoptive T cell therapy of multiple myeloma (MM). In this study, we evaluated self-differentiated monocyte-derived dendritic cells expressing BCMA (SD-DC-BCMA) to activate T cells for killing MM cells. Materials and Methods: Lentivirus-modified SD-DC-BCMA harboring tri-cistronic cDNAs encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and BCMA was generated. Cytotoxicity of T cells activated by SD-DC-BCMA against MM cells was evaluated. Results: T cells activated by SD-DC-BCMA exhibited a dose-dependent cytotoxicity against BCMA-expressing MM cells and produced high IFN-γ levels, compared to inactivated T cells or control T cells. A significantly higher killing ability of T cells activated by SD-DC-BCMA was further demonstrated in BCMA-overexpressing cells when compared with BCMA-negative cells. Conclusion: The potency of SD-DC-BCMA to activate T cells for antigen-specific cancer killing provides a framework for therapeutic application of adoptive T cell therapy in MM.

KW - B cell maturation antigen

KW - Multiple myeloma

KW - adoptive T cell therapy

KW - cytotoxic T cells

KW - dendritic cells

UR - https://www.scopus.com/pages/publications/85127282821

U2 - 10.21873/anticanres.15655

DO - 10.21873/anticanres.15655

M3 - Article

C2 - 35346997

AN - SCOPUS:85127282821

SN - 0250-7005

VL - 42

SP - 1785

EP - 1799

JO - Anticancer Research

JF - Anticancer Research

IS - 4

ER -

Cytotoxic T Cells Activated by Self-differentiated Monocytederived Dendritic Cells Against Multiple Myeloma Cells

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this